CXCR4(S338X) clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia

CXCR4(S338X) clonality ≥25% is associated with lower very good partial response and shorter progression-free survival to ibrutinib. CXCR4(S338X) clonality assessment represents a novel biomarker to predict outcomes to ibrutinib in Waldenström macroglobulinemia patients.

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood Adv
Main Authors: Gustine, Joshua N., Xu, Lian, Tsakmaklis, Nicholas, Demos, Maria G., Kofides, Amanda, Chen, Jiaji G., Liu, Xia, Munshi, Manit, Guerrera, Maria Luisa, Chan, Gloria G., Patterson, Christopher J., Keezer, Andrew, Meid, Kirsten, Dubeau, Toni, Yang, Guang, Hunter, Zachary R., Treon, Steven P., Castillo, Jorge J.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2019
Teme:
Stimulus Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784519/
https://ncbi.nlm.nih.gov/pubmed/31570491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000635
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki